Fineline Cube

Follow:
14486 Articles
Henlius Biotech's HLX04-O Accepted by NMPA for Wet AMD Treatment
CompanyDrug

Henlius Biotech’s HLX04-O Accepted by NMPA for Wet AMD Treatment

TYK Medicines' Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC
CompanyDrug

TYK Medicines’ Asandeutertinib Shows Promising Results in Phase II Trial for EGFR-Mutated NSCLC

CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma
CompanyDeals

CANbridge Pharmaceuticals Secures HK 100 Million Equity Financing From Baheal Pharma

Kangji Medical Proposes Privatization, Aiming to Delist from Hong Kong Stock Exchange
CompanyDeals

Kangji Medical Proposes Privatization, Aiming to Delist from Hong Kong Stock Exchange

Hengrui Pharmaceuticals Expands Hetrombopag Olamine's Indication for ITP Patients
CompanyDrug

Hengrui Pharmaceuticals Expands Hetrombopag Olamine’s Indication for ITP Patients

Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment
Others

Ascletis Pharma Reports Positive Preclinical Results for ASC47 in Obesity Treatment

Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor
CompanyDeals

Bayer Collaborates with Kumquat Biosciences to Develop KRAS G12D Inhibitor

Sino Biopharmaceutical's TQB3142 IND Application Accepted by China's NMPA for Malignant Tumor Treatment
CompanyDrug

Sino Biopharmaceutical’s TQB3142 IND Application Accepted by China’s NMPA for Malignant Tumor Treatment

Novartis' Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia
CompanyDrug

Novartis’ Leqvio Approved by FDA as Standalone Therapy for Hypercholesterolemia

HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD
CompanyDeals

HighTide Therapeutics Collaborates with IMB to Assess HTD1801 in T2DM with CKD

FDA Launches PreCheck Program to Strengthen U.S. Pharmaceutical Supply Chain
Policy / Regulatory

FDA Launches PreCheck Program to Strengthen U.S. Pharmaceutical Supply Chain

Pfizer Restructures Oncology and Rare Disease Units for Enhanced Focus
Company

Pfizer China Restructures Oncology and Rare Disease Units for Enhanced Focus